A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

NCT00162110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Mucinous Gastrointestinal Adenocarcinoma

Interventions

DRUG: cetuximab

Sponsor

Eli Lilly and Company